This site is intended for healthcare professionals

Keytruda + chemotherapy filed at FDA supplemental sBLA as first-line treatment for locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Read time: 1 mins
Last updated:28th Jun 2021
Published:24th Dec 2020
Condition: Oesophageal Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest